Gentak

Inflammation, Ecthyma, Eczema + 36 more

Treatment

11 FDA approvals

20 Active Studies for Gentak

What is Gentak

Gentamicin

The Generic name of this drug

Treatment Summary

Gentamicin is an antibiotic that was discovered in 1963. It is widely prescribed due to its ability to fight both gram-positive and gram-negative bacteria, especially Pseudomonas aeruginosa. Gentamicin works well when combined with other antibiotics, which can reduce the amount of drug required and minimize side effects. However, gentamicin can cause serious side effects such as kidney and hearing damage, so it should be used with caution.

Gentamicin

is the brand name

image of different drug pills on a surface

Gentak Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Gentamicin

Gentamicin

1982

125

Approved as Treatment by the FDA

Gentamicin, also called Gentamicin, is approved by the FDA for 11 uses including Communicable Diseases and severe Infection Pseudomonas aeruginosa .

Communicable Diseases

Used to treat Susceptible infections in combination with Betamethasone

severe Infection Pseudomonas aeruginosa

Used to treat severe Infection Pseudomonas aeruginosa in combination with Carbenicillin

severe Endocarditis enterococcal

Used to treat severe Endocarditis enterococcal in combination with Benzylpenicillin

Inflammation

Used to treat Inflammation in combination with Betamethasone

Bacterial Infections

Skin Infections

Used to treat Skin Infections in combination with Betamethasone

Inflammation

Used to treat Inflammation in combination with Betamethasone

Communicable Diseases

Used to treat severe Infection Pseudomonas aeruginosa in combination with Carbenicillin

Communicable Diseases

Used to treat Skin Infections in combination with Betamethasone

Endocarditis

Used to treat severe Endocarditis enterococcal in combination with Benzylpenicillin

Urinary Tract Infection (UTI)

Effectiveness

How Gentak works in the body

Aminoglycosides work in two ways to kill bacteria. First, they bind to the cell membranes of bacteria, which weakens the membrane and allows the medicine to enter. Once inside, the medicine binds to the ribosome, which is responsible for making proteins. This causes the proteins to be made incorrectly, which weakens the cell membrane further and prevents the cell from reproducing. Finally, the medicine accumulates in the cell, causing it to die. Aminoglycosides are not effective against anaerobic bacteria since they require oxygen for transport.

When to interrupt dosage

The suggested portion of Gentak is reliant upon the diagnosed situation, for instance Blepharitis, Corneal infection and Dermatitis infected. The amount of dosage additionally fluctuates as per the technique of delivery (e.g. Intravenous or Liquid - Ophthalmic; Topical) indicated in the table beneath.

Condition

Dosage

Administration

Conjunctivitis, Bacterial

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Keratoconjunctivitis

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

ocular bacterial infections

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Blepharoconjunctivitis

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Pustular acne

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Skin Diseases

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Impetigo contagious

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Endocarditis

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Bacterial Infections

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Urinary Tract Infections

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Conjunctivitis

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Communicable Diseases

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Inflammation

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Eczema

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Pyoderma Gangrenosum

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Corneal infection

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Dacryocystitis

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Meibomianitis

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Sycosis barbae

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Sycosis

0.001 mg/mg, , 10.0 mg/mL, 40.0 mg/mL, 1.2 mg/mL, 1.4 mg/mL, 1.6 mg/mL, 0.8 mg/mL, 0.9 mg/mL, 1.0 mg/mL, 0.003 mg/mg, 3.0 mg/mL, 0.3 %, 0.1 %, 4.5 mg, 6.0 mg/mL, 8.0 mg/mL, 0.6 mg/mL, 0.4 mg/mL, 12.0 mg/mL, 5.0 mg/mL, 0.005 mg/mg

, Topical, Cream, Ointment, Ointment - Topical, Cream - Topical, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Injection, solution - Intravenous, Ophthalmic, Solution, Ointment - Ophthalmic, Solution - Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection, solution, concentrate - Intramuscular; Intravenous, Solution - Intravenous, Liquid - Ophthalmic, Auricular (otic), Solution - Auricular (otic), Liquid, Solution / drops - Auricular (otic), Solution - Intramuscular; Intravenous, Auricular (otic); Ophthalmic, Solution - Auricular (otic); Ophthalmic, Ointment - Ophthalmic; Topical, Liquid - Ophthalmic; Topical, Liquid - Intramuscular; Intravenous, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Implant, Implant - Parenteral, Parenteral, Liquid - Auricular (otic); Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops

Warnings

Gentak has two contraindications, thus it should not be taken concurrently with the conditions listed in the following table.

Gentak Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Gentamicin may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Gentamicin may interact with Pulse Frequency

There are 20 known major drug interactions with Gentak.

Common Gentak Drug Interactions

Drug Name

Risk Level

Description

Agalsidase beta

Major

The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Gentamicin.

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Gentamicin is combined with Neomycin.

Tenofovir

Major

Gentamicin may increase the nephrotoxic activities of Tenofovir.

Tenofovir alafenamide

Major

Gentamicin may increase the nephrotoxic activities of Tenofovir alafenamide.

Tenofovir disoproxil

Major

Gentamicin may increase the nephrotoxic activities of Tenofovir disoproxil.

Gentak Toxicity & Overdose Risk

Gentamicin has been linked to kidney and ear damage, with symptoms including increased creatinine and urea levels in the blood, balance issues, nausea, tinnitus, and hearing loss. Long-term use of gentamicin increases the risk of these toxicities and may lead to permanent ear damage. To reduce the risk of toxicity, patients should be closely monitored and the medication stopped immediately in cases of toxicity or overdose. Hemodialysis may also be used to lower gentamicin serum concentrations.

image of a doctor in a lab doing drug, clinical research

Gentak Novel Uses: Which Conditions Have a Clinical Trial Featuring Gentak?

219 active clinical trials are currently underway to investigate the potential of Gentak to reduce Inflammation, Ocular Inflammation and Allergic Conjunctivitis (AC).

Condition

Clinical Trials

Trial Phases

Inflammation

58 Actively Recruiting

Not Applicable, Early Phase 1, Phase 1, Phase 2, Phase 3, Phase 4

Bacterial Infections

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Keratitis

0 Actively Recruiting

Sycosis barbae

0 Actively Recruiting

Blepharoconjunctivitis

0 Actively Recruiting

Keratoconjunctivitis

0 Actively Recruiting

Pustular Psoriasis (PP)

0 Actively Recruiting

Ecthyma

0 Actively Recruiting

Impetigo contagious

0 Actively Recruiting

ocular bacterial infections

0 Actively Recruiting

Dacryocystitis

0 Actively Recruiting

Staphylococcal Infections

0 Actively Recruiting

Urinary Tract Infections

0 Actively Recruiting

Bacterial Peritonitis

0 Actively Recruiting

Pyoderma Gangrenosum

2 Actively Recruiting

Phase 2, Phase 3

Pustular acne

0 Actively Recruiting

Endocarditis

0 Actively Recruiting

Allergic Conjunctivitis (AC)

1 Actively Recruiting

Phase 2

Sycosis

0 Actively Recruiting

Gentak Reviews: What are patients saying about Gentak?

3.3

Patient Review

9/28/2011

Gentak for Bacterial Infection of the Eyelid

I unfortunately had an allergic reaction to the medication.

1.7

Patient Review

9/16/2011

Gentak for Inflammation of Eyelid Edges and the Lining of the Eye

My eye was very itchy on the edges, so I saw a doctor. They said I had an infection and prescribed this medication. Three times a day for three days. It's now been three days and my eyes are no better; in fact, they might even be worse.

1.7

Patient Review

5/11/2012

Gentak for Pink Eye from Bacterial Infection

I found this easy enough to use, but unfortunately it didn't work for me.

1.3

Patient Review

6/28/2011

Gentak for Bacterial Infection of the Eyelid

Gentak was prescribed by my doctor to treat a stye. However, after just two days of use, both of my eyes had swollen shut. Additionally, the eyelids had developed horrible blisters. The medicine in the eye that didn't have the stye caused eye blisters and ulcers. Consequently, I would not recommend this medication to anyone.

1.3

Patient Review

1/3/2015

Gentak for Bacterial Infection of the Eyelid

I was prescribed this ointment for conjunctivitis, but it is very difficult to apply. After four days of the five-day treatment, I stopped using it because of the pain, burning, and itchiness. I'll have to go back to the doctor.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about gentak

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Gentak used for pink eye?

"Gentamicin is an antibiotic that is used to treat bacterial infections of the eye and eyelid. This medication can be given after eye surgery or injury to help prevent bacterial infections from happening."

Answered by AI

What is Gentak ointment used for?

"This medication is used to treat bacterial infections of the eye, such as blepharitis and conjunctivitis, and the skin around the eyes, such as eyelids. It is also used to prevent infection after eye injury or surgery. It belongs to a class of drugs known as aminoglycoside antibiotics."

Answered by AI

Is Gentak still made?

"Akorn has stopped making Gentak."

Answered by AI

Is Gentak a prescription?

"Gentak is a medicine used to treat the symptoms of Conjunctivitis (pink eye) and to prevent infections after surgery. Gentak may be used alone or with other medications."

Answered by AI

Clinical Trials for Gentak

Image of Montana State University in Bozeman, United States.

Haskap Berries for Exercise Performance Recovery

18 - 35
All Sexes
Bozeman, MT

The purpose of this clinical trial is to determine how certain food items affect oxidative stress, inflammation, and performance recovery from exercise induced muscle damage in a resistance trained population. The main questions The investigators aim to answer are the following: * Do Haskaps speed the recovery of oxidative stress and inflammation markers after an intense lower body workout in resistance trained adults? * Do Haskaps speed the recovery of performance measures after an intense lower body workout in resistance trained adults? * The data collected in this investigation may also be used to ask additional questions not yet identified. For example, the investigators may use the stored samples to evaluate how the blood metabolites of participants differ before and after intense exercise. These additional questions are called secondary analyses. Please note that no genetic analysis will be conducted and racial and ethnic differences among participants will not be used in any secondary analyses. Researches will compare Haskap juice to a color, flavor and carbohydrate matched placebo to see if Haskaps speed recovery in inflammation, oxidative stress and performance. * Participants will be asked to drink either Haskap juice or placebo and follow a low polyphenolic diet * Participants will perform an intense resistance workout * Participants will have their blood drawn before and after the workout * Performance will be analyzed at 24, 48 and 72 hours after the workout

Recruiting
Paid Trial

Montana State University

Mary P Miles

Image of University of New Brunswick in Fredericton, Canada.

Mediterranean Diet for Toddler Health

24 - 36
All Sexes
Fredericton, Canada

Toddlerhood (ages 2-3) is a critical window when the gut microbiome is still developing and eating habits are being established. Yet, many Canadian toddlers eat diets high in sugar and salt, which may affect long-term health. This study will test whether a MED diet can improve dietary inflammation, gut health, and body composition in toddlers and whether a tailored nutrition education program for parents can help families maintain healthy eating patterns. In this study, toddlers will be randomly assigned to a 3-week MED diet or their usual diet. Families in the MED diet group will receive free meal boxes for the 3 weeks, plus guidance from a nutrition researcher through a structured education program. The standard diet group will continue their regular diet with general nutrition advice. Researchers will collect dietary information, body composition assessments, and stool samples to measure gut microbiome composition and metabolites. This first study of a controlled diet intervention in toddlers, combining behavioral support, high-quality food provision, and advanced gut microbiome analysis, will help understand how early diet shapes lifelong eating habits and health, guiding public health strategies and precision nutrition approaches to prevent chronic disease from early life.

Waitlist Available
Has No Placebo

University of New Brunswick

Dr. Maryam Kebbe, PhD, CLC

Have you considered Gentak clinical trials?

We made a collection of clinical trials featuring Gentak, we think they might fit your search criteria.
Go to Trials
Image of Department of Nutritional Sciences in Storrs, United States.

Freeze-dried Grape Powder for Healthy Aging

50 - 75
All Sexes
Storrs, CT

The purpose of this study is to investigate the effects of consuming grape powder on immune profiles in healthy middle- and older-aged individuals. Specifically, the investigators are interested in evaluating the potential effects of grapes in influencing markers of immune function, inflammation, and metabolism that are known to change with aging. Grapes contain several nutrients and antioxidant polyphenols such as resveratrol, quercetin, vitamin K and fiber, which are known to promote heart and immune health. However, the effects of grapes on altering immune profiles within the context of aging is not well understood. Therefore, this study will explore how daily grape consumption impacts certain markers of immunity in healthy middle- and older-aged adults. The main study procedures include consumption of a freeze-dried grape powder and control powder (which tastes the same but has none of the grape compounds that are being studied) mixed with water as a beverage on a daily basis for 4 weeks each. The investigators will additionally ask that participants avoid eating grapes and certain other antioxidant/grape-related foods and beverages throughout the 13-week study. Participants will additionally be asked to complete surveys about their diet, physical activity, and medical history, as well as provide blood samples and body weight measures throughout the course of the study. Participation in the study is expected to last about 6.25 hours over the course of 13 weeks and will include 7 visits.

Recruiting
Paid Trial

Department of Nutritional Sciences

Image of Abcentra Investigational Site in Los Angeles, United States.

Orticumab for Heart Attack

18+
All Sexes
Los Angeles, CA

The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies

Phase 2
Recruiting

Abcentra Investigational Site (+6 Sites)

Abcentra

Have you considered Gentak clinical trials?

We made a collection of clinical trials featuring Gentak, we think they might fit your search criteria.
Go to Trials
Image of Tesla MedBed at Tampa-FL in Tampa, United States.

Biophoton Therapy for Stem Cell Proliferation

18 - 70
All Sexes
Tampa, FL

Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can increase self-grown stem cells naturally. Study Design This is a randomized, double-blinded, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in impacting stem cells. Approximately 46 volunteers who want to increase self-grown stem cells will participate in the study. Study Randomization The biostatistician will prepare a randomization schedule including a serial of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group. Other than the Informed Consent Form (ICF), all study information will be recorded by using the subject number. The Principal Investigator, study physicians, study nurse, data-entry specialists, and biostatisticians, as well as the participants, will be blinded about who received which product during the first two weeks of study participation.

Recruiting
Online Trial

Tesla MedBed at Tampa-FL (+1 Sites)

James Z Liu, MD, PhD

Image of Goldring Center for High Performance Sport in Toronto, Canada.

Physical Activity for Delayed Onset Muscle Soreness

18 - 35
All Sexes
Toronto, Canada

After completing novel activity or exercise we may experience exercise-induced muscle damage (EIMD), resulting in a period of reduced muscle function and delayed onset muscle soreness (DOMS). DOMS is characterized by muscle pain and tenderness that typically resolves within a week. While the precise cause of DOMS is unknown, there is growing evidence implicating damage to the connective tissue that surrounds our muscle fibers and is related to a small amount of inflammation. This inflammation is a normal part of our body's ability to recovery from injuries and may be visualized through the use of ultrasound technology. A variety of recovery techniques have been proposed that may help with the recovery of DOMS such as massage and electrical muscle stimulation, but these are not always accessible. Therefore, we are interested in investigating whether the number of daily steps can affect how you experience DOMS.

Waitlist Available
Has No Placebo

Goldring Center for High Performance Sport

Image of UCSF in San Francisco, United States.

Moisturizers for Aging

65+
All Sexes
San Francisco, CA

This is a randomized, investigator-blinded, self-controlled pilot study of the physiologic response to topical moisturizers among older adults with dry skin. The overarching hypothesis is that skin barrier decline is an important source of chronic inflammation, and that skin barrier restoration with moisturizers can reduce serum biomarkers of inflammation. The primary objective is to determine the feasibility for a larger trial, and the secondary objectives are to determine the extent to which measures of serum inflammation, skin barrier function, and the skin microbiome change in response to moisturizers. Participants will be asked to apply one of two topical moisturizers that are widely available over the counter in the US (Vaseline® 100% pure petroleum jelly or CeraVe® moisturizing cream) once daily for 4 weeks to the front of the torso, buttocks, arms, and legs. Subjects will act as their own control (i.e. they will be asked to apply the study moisturizer they are randomized to for one intervention period (4 weeks) and not to apply topical moisturizers for the other 4- week intervention period). Participants will be randomized in a 1:1:1:1 ratio to one of 4 treatment groups: i. no intervention then CeraVe; ii. CeraVe then no intervention; iii. no intervention then Vaseline; iv. Vaseline then no intervention. At each visit (baseline, week 4, and week 8), participants will undergo skin barrier testing, skin microbiome sampling, and phlebotomy to measure serum inflammatory markers.

Phase 4
Recruiting

UCSF

Katrina Abuabara, MD

Have you considered Gentak clinical trials?

We made a collection of clinical trials featuring Gentak, we think they might fit your search criteria.
Go to Trials